drugset / Trial / NCT04210141

Optimal Dose of Antivenom for Daboia Siamensis Envenomings

NCT04210141 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to identify an 'optimal' initial dosing of the new Burma Pharmaceutical Industry (BPI) lyophilized mono-specific antivenom for patients with systemic Daboia siamensis envenoming. The initial dosing will aim to reverse venom-induced coagulopathy (as demonstrated by a negative 20 minutes Whole Blood Clotting Time (20WBCT) at 6 hours in 95% of patients whilst causing less than 5% anaphylactic reaction.

Timeline

Start
2025-04
Primary completion
2027-02-01
Completion
2027-11-01

Outcome

Outcome not reported

Stopped: “due to current political circumstances in study site area.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject BPI viper antivenom Protein / enzyme biologic 80 ml —
Subject BPI viper antivenom Protein / enzyme biologic 160 ml —